An analytically and diagnostically sensitive RNA extraction and RT-qPCR protocol for peripheral blood mononuclear cells by Browne, Daniel J. et al.
ORIGINAL RESEARCH
published: 20 March 2020
doi: 10.3389/fimmu.2020.00402
Frontiers in Immunology | www.frontiersin.org 1 March 2020 | Volume 11 | Article 402
Edited by:
Urszula Krzych,
Walter Reed Army Institute of
Research, United States
Reviewed by:
Irfan Zaidi,
National Institutes of Health (NIH),
United States
Ann M. Moormann,
University of Massachusetts Medical
School, United States
*Correspondence:
Denise L. Doolan
denise.doolan@jcu.edu.au
†These authors have contributed
equally to this work and share last
authorship
Specialty section:
This article was submitted to
Vaccines and Molecular Therapeutics,
a section of the journal
Frontiers in Immunology
Received: 16 November 2019
Accepted: 20 February 2020
Published: 20 March 2020
Citation:
Browne DJ, Brady JL,
Waardenberg AJ, Loiseau C and
Doolan DL (2020) An Analytically and
Diagnostically Sensitive RNA
Extraction and RT-qPCR Protocol for
Peripheral Blood Mononuclear Cells.
Front. Immunol. 11:402.
doi: 10.3389/fimmu.2020.00402
An Analytically and Diagnostically
Sensitive RNA Extraction and
RT-qPCR Protocol for Peripheral
Blood Mononuclear Cells
Daniel J. Browne1, Jamie L. Brady 1, Ashley J. Waardenberg 1,2, Claire Loiseau1† and
Denise L. Doolan 1,2*†
1 Centre for Molecular Therapeutics, Australian Institute of Tropical Health & Medicine, James Cook University, Cairns, QLD,
Australia, 2 Centre for Tropical Bioinformatics and Molecular Biology, Australian Institute of Tropical Health & Medicine, James
Cook University, Cairns, QLD, Australia
Reliable extraction and sensitive detection of RNA from human peripheral blood
mononuclear cells (PBMCs) is critical for a broad spectrum of immunology research
and clinical diagnostics. RNA analysis platforms are dependent upon high-quality
and high-quantity RNA; however, sensitive detection of specific responses associated
with high-quality RNA extractions from human samples with limited PBMCs can be
challenging. Furthermore, the comparative sensitivity between RNA quantification and
best-practice protein quantification is poorly defined. Therefore, we provide herein a
critical evaluation of the wide variety of current generation of RNA-based kits for PBMCs,
representative of several strategies designed to maximize sensitivity. We assess these
kits with a reverse transcription quantitative PCR (RT-qPCR) assay optimized for both
analytically and diagnostically sensitive cell-based RNA-based applications. Specifically,
three RNA extraction kits, one post-extraction RNA purification/concentration kit, four
SYBR master-mix kits, and four reverse transcription kits were tested. RNA extraction
and RT-qPCR reaction efficiency were evaluated with commonly used reference and
cytokine genes. Significant variation in RNA expression of reference genes was apparent,
and absolute quantification based on cell number was established as an effective
RT-qPCR normalization strategy. We defined an optimized RNA extraction and RT-qPCR
protocol with an analytical sensitivity capable of single cell RNA detection. The diagnostic
sensitivity of this assay was sufficient to show a CD8+ T cell peptide epitope hierarchy
with as few as 1 × 104 cells. Finally, we compared our optimized RNA extraction and
RT-qPCR protocol with current best-practice immune assays and demonstrated that our
assay is a sensitive alternative to protein-based assays for peptide-specific responses,
especially with limited PBMCs number. This protocol with high analytical and diagnostic
sensitivity has broad applicability for both primary research and clinical practice.
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INTRODUCTION
Reliable isolation of high quality and high quantity RNA
from peripheral blood mononuclear cells (PBMCs) and other
cells is critical for a broad range of basic, preclinical, and
clinical applications (1, 2). RNA-based assays enable analysis of
basal expression profiles and responses to antigen or mitogen
stimulation (3, 4). Human PBMCs are a common source of
RNA as collection of blood is less invasive and allows in-depth
monitoring of many aspects of immunobiology (1, 5) including
identification, classification and prognosis of cancers (6–11)
monitoring inflammation (12, 13), and evaluating therapeutic
efficacy (14–17).
A range of RNA-based platforms are now available, all
dependent upon high quality and high quantity RNA (1).
However, an important requirement for many applications is
both excellent analytical sensitivity (i.e., smallest number of cells
detectable) and diagnostic sensitivity (i.e., smallest detectable
response to stimulation) (18). Protein-level immunoassays (e.g.,
flow cytometry, cytokine bead-based arrays, ELIspot) (19–22) are
routinely used to detect PBMCs response to stimulation (23–25).
Indeed, ELIspot has been used extensively as the “gold standard”
immune assay given its sensitivity and has been optimized and
validated as part of the global HIV/AIDS Comprehensive T Cell
Vaccine Immune Monitoring Consortium (26–28). However,
these protocols are limited by the relatively high number of
cells required, especially when considering targets with low
frequencies (24), when collection of large blood volumes is
challenging (29, 30), or when there are many experimental
variables [e.g., vaccine/peptide (14, 17, 31, 32) or epitope testing
(33–35)]. Therefore, there is an unmet need for a robust RNA
extraction and transcriptomic analysis protocol from limited
input cell numbers (e.g., PBMCs) with high analytical and
diagnostic sensitivity that meets or exceeds that of protein-
level immuno-assays.
Reverse transcription quantitative PCR (RT-qPCR) remains
the “Gold Standard” for assay of gene expression as an alternate
readout to protein expression (36, 37). RT-qPCR ismore sensitive
than traditional RNA quantification technologies (i.e., Northern
blotting, nuclease protection assays, in-situ hybridization, RNA
microarrays etc.) (38–40). More recent technologies such as
Sanger and next-generation sequencing (i.e., RNA-Seq, single
cell RNA-seq, NanoString) and advanced PCR methods (i.e.,
digital PCR) are similarly sensitive (41, 42) but are relatively
expensive or further require complex bioinformatical analysis
(43, 44). In contrast, our optimized RT-qPCR assay is designed
specifically for cheap, robust, reproducible and sensitive analysis
of gene expression, is available to almost any laboratory, and
serves as a sensitive and specific alternative to protein expression.
Additionally, by focusing on a limited number of genes, RT-qPCR
is ideal for validation of genes of interest identified from more
untargeted methods such as RNAseq.
However, there is an unmet need for a robust RNA
extraction and RT-qPCR protocol with excellent analytical and
diagnostic sensitivity, ideally to the single cell level. An important
consideration for such a protocol is that RT-qPCR normalization
can be achieved by either absolute quantification of copies per
reaction using a standard curve, or by semi-quantitative fold-
change of relative expression normalized to reference genes (39,
45). However, in vitro stimulation has been shown to modulate
the expression of many commonly used reference genes (46,
47), and key assumptions underlying semi-quantitative analysis
require consistent reference gene expression across experimental
conditions within and amongst cell populations. An alternative
is absolute quantification normalized to cell number, which
minimizes this potential analytical bias (48–50).
To address this need, we developed a highly sensitive RNA
extraction and RT-qPCR quantification strategy for analysis
of gene expression from human PBMCs. We compared
the efficiency of the latest generation of SYBR master-
mixes and RNA extraction and reverse transcription kits,
taking into consideration both total RNA yield and RNA
concentration. We determined that ssoAdvancedTM Universal
SYBR R© Green Master-Mix provided optimal reaction efficiency,
whilst SuperScriptTM IV Reverse Transcriptase had the highest
cDNA yields. We demonstrated significantly increased PBMC
RNA recovery following extraction with themagnetic bead-based
MagMAXTM mirVanaTM kit, with no further enhancement of
analytical sensitivity by including an additional step of RNA
concentration. When testing the analytical sensitivity of our
optimized protocol, we could detect RNA to the single cell level
of highly expressed genes. Furthermore, by evaluating a hierarchy
of CD8+ T cell epitope responses, we demonstrated diagnostic
sensitivity with as few as 1 × 104 PBMCs. This optimized
RNA extraction and RT-qPCR protocol, with high analytical and
diagnostic sensitivity, provides a robust alternative to protein-
based immune assays.
MATERIALS AND EQUIPMENT
PBMC Stimulatory Reagents
- Phorbol 12-Myristate 13-Acetate (PMA), (Sigma-Aldrich)
- Ionomycin (Iono), (Sigma-Aldrich)
- Phytohemagglutinin-L (PHA), (Sigma-Aldrich)
- Human Cytomegalovirus, Epstein Barr Virus and Influenza
virus Synthetic peptides (Table 1).
SYBR Mastermix Kits:
- ssoAdvancedTM Universal SYBR R© Green Master-Mix (Bio-
Rad)
- QuantiNova SYBR R© Green PCR Kit (QIAGEN).
TABLE 1 | Synthetic peptides.
Code Amino acid sequence HLA resriction Species
VTE VTEHDTLLY A1 Cytomegalovirus
GIL GILGFVFTL A2 Influenza
RPH RPHERNGFTVL B7 Cytomegalovirus
FLR GILGFVFTL B8 Epstein Barr Virus
Characteristics of synthetic peptides representing defined CD8+ T cell peptide epitopes
derived from CMV, EBV and influenza virus restricted by the MHC-class I molecules
HLA-A1, -A2, -B7, and -B8.
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- PowerUp SYBR R© Green Master-Mix (Applied Biosystems)
- RT² SYBR R© Green qPCR Master-Mix (QIAGEN).
RNA Extraction Kits
- RNeasy R© Mini Kit (QIAGEN)
- RNeasy R© MiniElute Cleanup Kit (QIAGEN)
- RNeasy R© Micro Kit (QIAGEN)
- MagMAXTM mirVanaTM Total RNA Isolation Kit
(Applied Biosystems).
RNA to cDNA Synthesis Kits
- SuperScriptTM III First-Strand Synthesis System
(ThermoFisher)
- SuperScriptTM IV First-Strand Synthesis
System (ThermoFisher)
- iScriptTM Advanced cDNA Synthesis Kit (Bio-Rad)
- High-Capacity RNA-cDNA KitTM (Applied Biosystems).
Quantitative PCR Primers
- PrimerBankTM primers (Table 2).
Antibodies
- anti-human IFN-γ monoclonal antibody (mAb) (Clone 1-
D1K, MABTECH)
- anti-human IFN-γ biotinylated mAb (Clone
7-B6-1, MABTECH)
- anti-human IFN-γ-FITC mAb (Clone 4S.B3, BD Biosciences).
Equipment
- QuantStudio 3 Real-Time PCR system (Applied Biosystems)
- NanoDrop 2000 Spectrophotometer (ThermoFisher)
- 2100 Bioanalyzer (Agilent Technologies)
- AID ELIspot reader system (Autoimmun Diagnostika
GmbH, Germany)
- LSRFortessa X-20 (BD Biosciences).
Software
- QuantStudio Design and Analysis Software (v1.4.3,
Applied Biosystems)
- ProcartaPlex Analyst Software (v1.0, ThermoFisher)
- FlowJo Software (v10.4, BD Biosciences)
- GraphPad Prism (v7, GraphPad).
METHODS
Samples
PBMCs
Blood was collected from healthy donors or buffy coats (n = 12)
provided by the Australian Red Cross Blood Service, under
a protocol approved by the James Cook University Human
Research Ethics Committee (#H6702). PBMCs were isolated by
density gradient centrifugation and cryopreserved in FBS 10%
DMSO. Prior to use, samples were thawed rapidly at 37◦C,
treated with DNAase I (1µg/mL; StemCell), and rested for 18 h
at 2 × 106 cells/mL in media (RPMI-1640, 10% FBS, 100 U/mL
penicillin/streptomycin) at 37◦C and 5% CO2. Viable PBMCs
were counted prior to downstream analysis.
HLA Typing
Genomic DNA was isolated from PBMCs using the QIAamp
DNA Mini Kit (QIAGEN) according to manufacturer’s
instructions. High-resolution class I and class II HLA typing
was performed by the Australian Red Cross Transplant and
Immunological Services (Melbourne, Australia) using the MIA
FORA NGS FLEX HLA typing kit (Immunocor) and Illumina
MiSeq and MiniSeq platforms.
Cell Stimulation
PBMCs were resuspended in RPMI-1640 supplemented
with 10% human serum, 100 U/mL penicillin/streptomycin,
2mM glutaMAX (ThermoFisher Scientific), 10mM HEPES
(ThermoFisher Scientific), and 5 × 10−5 M β-Mercaptoethanol
(Sigma-Aldrich) (complete media). Synthetic peptides
(10µg/mL) representing defined CD8+ T cell epitopes from
human Cytomegalovirus, Epstein Barr Virus or Influenza virus
(Table 1) were tested alongside PMA/Iono (50 ng/mL PMA,
1,000 ng/mL Iono) and PHA (PHA; 1µg/mL) mitogen controls
as well as media-only negative control. PBMCs were stimulated
for 6, 12, 16, 24, or 48 h at 2 × 106 cells/mL in 200 µL in 96-well
U-bottom plates (qPCR, ELIspot and multiplexed bead array)
or at 1 × 106 cells/mL in 3mL in 12-well flat-bottom plates
(flow cytometry).
Quantitative PCR
Assay Setup
qPCR was conducted using the QuantStudio 3 Real-Time PCR
system running QuantStudio Design and Analysis Software
TABLE 2 | Primer list.
Transcript GenBank accession
number
PrimerBankTM
ID
Forward sequence
(5′-3′)
Reverse sequence
(5′-3′)
Amplicon size
(bp)
Reference genes
RPLA13a NM_012423 14591905c2 GCCCTACGACAAGAAAAAGCG TACTTCCAGCCAACCTCGTGA 117
SDHA NM_004168 156416002c3 TGGCATTTCTACGACACCGTG GCCTGCTCCGTCATGTAGTG 77
TBP NM_003194 285026518c2 CCCGAAACGCCGAATATAATCC AATCAGTGCCGTGGTTCGTG 80
Cytokine gene
IFN-γ NM_000619.2 56786137c1 TCGGTAACTGACTTGAATGTCCA TCGCTTCCCTGTTTTAGCTGC 93
Characteristics of primers acquired from PrimerBankTM database.
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(v1.4.3, Applied Biosystems). A standard curve, combined
calibration sample, and no template negative controls were
included on each plate. All samples were run in technical
triplicate in accordance with MIQE guidelines (45). cDNA
synthesis was conducted on a SimpliAmpTM thermocycler
(ThermoFisher Scientific). Unless specifically noted, all reaction
conditions and protocols were performed as recommended
by the manufacturer. Copies/reaction were determined by
absolute quantification.
SYBR Master-Mix Testing: Amplicon Standard
Four SYBR master-mix kits were evaluated: ssoAdvancedTM
Universal SYBR R© Green Master-Mix (Bio-Rad), QuantiNova
SYBR R© Green PCR Kit (QIAGEN), PowerUp SYBR R© Green
Master-Mix (Applied Biosystems) and RT² SYBR R© Green
qPCR Master-Mix (QIAGEN). RPL13a, SDHA, TBP, and IFN-γ
primer (Table 2) amplicons were purified by Wizard SV Gel &
PCR CleanUp System (Promega) and quantified by NanoDrop
2000 Spectrophotometer (ThermoFisher). Master-mix reaction
efficiency was calculated by amplification of amplicons titrated
from 107 to 101 copies/reaction, with primers at 250, 500, or 750
nM (45).
SYBR Master-Mix Testing: cDNA Standard
The four SYBR master-mix kits were further evaluated with
efficiency titrations of cDNA standards. Briefly, RNA was
extracted from 1× 106 unstimulated PBMCs using the RNeasy R©
Mini Kit (QIAGEN). Seven microliters of extracted RNA was
converted to cDNA using the SuperScriptTM III First-Strand
Synthesis System kit (Invitrogen). Master-mix reaction efficiency
was calculated from log10 diluted cDNA (104-101 cells/reaction)
with RPL13a, SDHA, TBP, and IFN-γ primers at 500 nM.
Reference Gene Stability Testing
1 × 106 PBMCs were stimulated for 6, 12, 16, 24, or 48 h with or
without PMA/Iono as described above. RNA was extracted with
RNeasy R© Mini Kit (QIAGEN). Seven microliters of extracted
RNA was reverse transcribed with SuperScriptTM III First-
Strand Synthesis System kit (Invitrogen). qPCR was run with
ssoAdvancedTM master-mix, RPL13a, SDHA, TBP and IFN-γ
primers at 500 nM and samples at 102 cells/reaction.
Evaluation of RNA Extraction Kits
To evaluate RNA yield and quality, three RNA extraction kits:
RNeasy R© Mini Kit (QIAGEN), RNeasy R© Micro Kit (QIAGEN),
and MagMAXTM mirVanaTM Total RNA Isolation Kit (Applied
Biosystems); and one post-extraction RNA purification and
concentration kit, RNeasy R© MiniElute Cleanup Kit (QIAGEN),
were evaluated. All extractions included genomic DNA removal.
RNA was extracted from 1 × 106 PBMCs incubated for
6 h with or without PMA/Iono, with the exception of the
RNeasy R© Micro Kit where 0.5 × 106 PBMCs was used (per
manufacturer’s recommendation). To evaluate concentration,
kit eluates were concentrated using the RNeasy R© MiniElute.
All elutions were performed in the smallest recommended
volume. The yield of extracted RNA was quantified using
a NanoDrop 2000 Spectrophotometer (ThermoFisher). RNA
yield (i.e., total RNA extracted), calculated RNA quality was
assessed by RNA integrity number (RIN) by the Australian
Genome Research Facility (Brisbane, Australia) using a 2100
Bioanalyzer (Agilent Technologies). Subsequently, 7 µL of RNA
was converted to cDNA using the SuperScriptTM III First-Strand
Synthesis System kit (Invitrogen) alongside negative reverse
transcriptase controls. qPCR was run with ssoAdvancedTM
master-mix, RPL13a, SDHA, TBP, and IFN-γ primers at 500nM
and sampled at 102 cells/reaction.
Evaluation of Reverse Transcription Kits
Four reverse transcription kits were evaluated: SuperScriptTM
III First-Strand Synthesis System (ThermoFisher Scientific),
SuperScriptTM IV First-Strand Synthesis System (ThermoFisher),
iScriptTM Advanced cDNA Synthesis Kit (Bio-Rad) or High-
Capacity RNA-cDNA KitTM (Applied Biosystems). Kits were
evaluated using RNA extracted using theMagMAXTM mirVanaTM
Total RNA Isolation Kit (MagMAX) with or without the
RNeasy R© MiniElute Cleanup Kit. Briefly, 1 × 106 PBMCs were
incubated for 6 h with or without PMA/Iono as described above.
Sevenmicroliter of RNA extracted byMagMAXwas used for each
cDNA synthesis kit. Alternatively, the maximum recommended
input of RNA extracted by MagMAX in association with the
RNeasy R© MiniElute Cleanup Kit was used (i.e., SuperscriptTM
III 7 µL, SuperscriptTM IV 10 µL, iScriptTM 14 µL, and High-
Capacity 9 µL). qPCR was run with ssoAdvancedTM master-
mix, RPL13a, SDHA, TBP, and IFN-γ primers at 500 nM and
sample diluted to 102 cells/reaction; except when considering
concentration, when the samples were run undiluted.
Analytical and Diagnostic Sensitivity
For determination of analytical sensitivity, RNA was extracted
from a log10 serial dilution of unstimulated PBMCs (106-
100 cells/extraction), using the MagMAX kit with or without
the RNeasy R© MiniElute Cleanup Kit. A media-only extraction
control was processed in parallel. For determination of diagnostic
sensitivity, RNA was extracted using the MagMAX kit from
titrated PBMCs (4 × 105, 1 × 105, 2.5 × 104, and 1 ×
104) incubated for 6 h with or without PMA/Iono or HLA-
matched peptide. For sensitivity evaluations, 10 µL of RNA
was converted to cDNA using the SuperScriptTM IV First-Strand
Synthesis System (Invitrogen). qPCR used undiluted sample with
ssoAdvancedTM master-mix, RPL13a, SDHA, TBP, and IFN-γ
primers at 500 nM.
Protein Quantification Assays
Enzyme-Linked Immunospot (ELIspot) Assay
IFN-γ ELIspot assays were performed as previously described
(51, 52). Briefly, 4 × 105 PBMCs were plated in triplicate onto
96-well multi-screen filtration plates (#MAIP S45-10, Merck)
pre-coated with anti-human IFN-γ monoclonal antibody (mAb)
(Clone 1-D1K, MABTECH) and stimulated for 24 h with or
without peptide, PMA/Iono, PHA or media. After washing,
IFN-γ secreting cells were stained with 1µg/mL of anti-human
IFN-γ biotinylated mAb (Clone 7-B6-1, MABTECH) followed
by streptavidin alkaline phosphatase (MABTECH). The assay
was developed using the AP Conjugate Substrate Kit (BioRad).
IFN-γ-spot-forming cells were counted using AID ELIspot
reader system (Autoimmun Diagnostika GmbH, Germany).
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FIGURE 1 | qPCR optimization. (A) Experimental workflow for qPCR optimization. (B) Effect of stimulation on mRNA expression of reference genes RPL13a, SDHA,
and TBP. 1 × 106 PBMCs paired samples were cultured with complete media (white), or stimulated with PMA/Iono control (gray) for 0, 6, 12, 16, 24, or 48 h. RNA
was extracted using the RNeasy® Mini (Mini) Kit, and reverse transcribed with SuperscriptTM III (Invitrogen). RNA expression was determined by absolute quantitative
RT-qPCR wherein number of gene copies per reaction was quantified by standard curve and normalized to cell number. Data were compared with a two-way ANOVA
with post-hoc Bonferroni’s multiple-comparisons test (**P ≤ 0.01; ***P ≤ 0.001). Biological replicate (n = 3) single RNA extractions with single reverse transcription
reactions per extraction were performed. Sample mean calculated from technical triplicate qPCR. Biological mean ± biological SEM are shown.
Multiplex Cytokine Bead Array
Supernatant was collected from 4 × 105 PBMCs incubated
for 6 h with or without peptide, PMA/Iono or media. Fifty
microliter supernatant was analyzed using the ProcartaPlex
Immunoassay (ThermoFisher) per manufacturer’s protocol.
Cytokine concentration was calculated from a standard curve
using the ProcartaPlex Analyst 1.0 Software (ThermoFisher).
Flow Cytometry
3 × 106 PBMCs were incubated for 6 h with or without peptide,
PMA/Iono or media. 5µg/mL brefeldin A (BD Biosciences)
was added after 1 h. Cells were then stained with Fixable
Viability Stain 510 (BD Bioscience) and permeabilizated with
the Cytofix/Cytoperm kit (BD Biosciences) before staining with
anti-human IFN-γ-FITC (Clone 4S.B3, BD Biosciences) mAb.
Data were acquired on a LSRFortessa X-20 driven by FACSDiva
software (BD Biosciences) and analyzed using FlowJo software
(version 10.4).
Data Analysis
RT-qPCR, Bioanalyzer andNanoDrop data were analyzed using a
repeated-measures two-way ANOVA with Bonferroni-corrected
multiple comparisons test comparing test to control mean.
Correlation between RT-qPCR and protein quantification was
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test with linear regression analysis. Analysis was conducted using
GraphPad Prism version 7.0 (GraphPad). In all cases, P < 0.05
were considered significant.
RESULTS
ssoAdvancedTM Universal SYBR® Green
Master-Mix Provided the Highest Reaction
Efficiency
Four master-mixes—ssoAdvancedTM Universal SYBR R© Green
Master-Mix (Bio-Rad), QuantiNova SYBR R© Green PCR Kit
(QIAGEN), PowerUp SYBR R© Green Master-Mix (Applied
Biosystems) and RT² SYBR R© Green qPCR Master-Mix
(QIAGEN)—were evaluated using two methods of preparing
reference standards: (i) standards derived from log10 diluted
amplicon; and (ii) standards generated from log10 diluted cDNA
(Figure 1A). Reaction efficiency was quantified using four
primer sets: three sets targeted reference genes known to have
high (60S ribosomal protein L13a; RPL13a), moderate (Succinate
dehydrogenase complex, subunit A; SDHA) and low (TATA-
binding protein; TBP) expression; and one set targeted a cytokine
gene (interferon gamma; IFN-γ ) (47). When considering an
acceptable reaction efficiency range (90–110%), 35.4% of the
amplicon-derived standards (Table 3) and 43.8% of the diluted
cDNA standards (Table 4) failed. Primer concentration did
not significantly affect mean deviation from 100% reaction
efficiency. Strikingly, when comparing SYBR master-mix kits
with cDNA standards, the use of ssoAdvancedTM had 0% failure
(efficiency: RPL13a 93.7%, SDHA 98.3%, TBP 95.9%, and IFN-γ
96.1%), the largest dynamic range (100−4 copies/reaction), and
the lowest mean deviation from 100% (Table 4). The coefficient
of determination of the standards (R2 ≥ 0.97) were consistent
for all primers tested, at all concentrations. Together, these data
identify ssoAdvancedTM master-mix as providing the highest
reaction efficiency for qPCR from PBMC cDNA.
Mitogen Stimulation Induced Changes in
RPL13a, SDHA, and TBP Gene Expression
The expression stability of three commonly used reference genes
(47, 53, 54), RPL13a, SDHA, and TBP, previously reported as
stable in PBMCs following stimulation (47), were evaluated
by RT-qPCR within PBMCs stimulated with PMA/Iono for
6, 12, 18, 24, or 48 h. Expression of all three genes changed
over time with cell culture, and significantly increased at
48 h post-stimulation as compared to baseline (P < 0.001, P
< 0.01, and P < 0.01, respectively; Figure 1B). These data
establish that the expression of common reference genes is
significantly affected by stimulation, emphasizing the importance
of absolute quantification normalized to cell numbers, rather
than relative quantification.
TABLE 3 | Evaluation of commercial qPCR master-mixes by amplicon derived standards.
QIAGEN R2
SYBR master-mix
QIAGEN QuantiNOVA
SYBR Master-mix
Bio-rad ssoadvanced
SYBR Master-mix
Applied biosystems
PowerUp SYBR
master-mix
[Primer] Transcript E′
(%)
LOD
(copies/
reaction)
R2 E′
(%)
LOD
(copies/
reaction)
R2 E′
(%)
LOD
(copies/
reaction)
R2 E′
(%)
LOD
(copies/
reaction)
R2 Primer
failure
rate (%)
250 nM
RPLA13a 92.2 101 0.99 94.9 102 0.99 89.1 101 0.99 92.0 101 0.99
31.3
SDHA 107.2 101 0.99 102.1 101 0.99 94.3 101 0.99 94.5 101 0.99
TBP 86.1 101 0.99 94.7 101 0.99 90.0 101 0.99 89.7 101 0.99
IFN-γ 93.6 101 0.99 85.8 101 0.98 83.9 102 0.99 99.7 101 0.98
250 nM failure rate 25.0% 25.0% 50.0% 25.0%
500 nM
RPLA13a 88.8 101 0.99 96.9 101 0.99 86.0 102 0.99 92.7 101 0.99
37.5
SDHA 93.8 101 0.99 93.5 102 0.99 92.4 101 0.99 90.8 101 0.99
TBP 88.6 101 0.99 82.6 102 0.99 89.2 101 0.99 98.4 101 0.99
IFN-γ 93.5 101 0.99 87.1 102 0.99 92.4 101 0.99 95.2 101 0.99
500 nM failure rate 50% 50% 50% 0%
750nM
RPLA13a 98.2 101 0.99 87.7 102 0.99 96.8 101 0.99 94.0 101 0.99
37.5
SDHA 98.0 101 0.99 104.2 101 0.99 102.1 101 0.99 92.3 102 0.97
TBP 86.7 102 0.99 89.2 101 0.99 87.2 101 0.99 85.5 102 0.99
IFN-γ 94.4 101 0.99 84.0 101 0.99 92.3 101 0.99 96.3 101 0.99
750 nM failure rate 25.0% 75.0% 25.0% 25.0%
Master-mix failure rate 33.3% 50.0% 41.7% 16.7%
Overall failure rate 35.4%
Commerical qPCR master-mixes were evaluated in combination with three primer concentrations (250, 500, and 750 nM) with logarithmically-diluted amplicon derived standards (106
to 101 copies amplicon per reaction). Assay performance i.e., reaction efficiency (E′ ), limit of detection (LOD) and standard coefficient of determination (R2 ) determined as per MIQE
guidelines. Amplicons were purified once and measured in qPCR technical triplicate. E′, Dynamic Range and R2 were calculated from the mean of the qPCR technical triplicates. Failure
rate calculated as percentage outside accceptable E′ (90–110%).
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TABLE 4 | Evaluation of commercial qPCR master-mixes by cDNA derived standards.
QIAGEN R2
SYBR master-mix
QIAGEN QuantiNOVA
SYBR master-mix
Bio-Rad ssoAdvanced
SYBR master-mix
Applied biosystems
PowerUp SYBR
master-mix
Transcript E′
(%)
Dynamic range
(cells/
reaction)
R2 E′
(%)
Dynamic range
(cells/
reaction)
R2 E′
(%)
Dynamic range
(cells/
reaction)
R2 E′
(%)
Dynamic range
(cells/
reaction)
R2
RPL13a 95.2 100–103 0.99 78.9 100–103 0.99 93.7 100–104 0.99 104.9 100–103 0.99
SDHA 79.9 100–103 0.99 85.7 100–103 0.99 98.3 100–104 0.99 121.5 100–103 0.99
TBP 134.7 102–104 0.99 99.1 102–104 0.99 95.9 101–104 0.99 109.7 102–104 0.99
IFN–γ 88.3 101–103 0.99 91.2 101–103 0.99 96.1 101–104 0.99 121.9 100–103 0.99
Master-mix failure rate 75.0% 50.0% 0.0% 50.0%
Overall failure rate 43.8%
Commerical qPCR master-mixes were evaluated with logarithmically diluted PBMC cDNA (104-101 cell cDNA equivalent per reaction). Assay performance, i.e., reaction efficiency (E′),
limit of detection (LOD) and standard coefficient of determination (R2 ) determined as per MIQE guidelines. Biological replicates (n = 3) were extracted with single reverse transcription
reactions per extraction, and measured in qPCR technical triplicate. RNA extractions were repeated. E′, Dynamic Range and R2 calculated from a representative technical extraction,
calculated from the mean of a qPCR technical replicate. Failure rate calculated as percentage outside accceptable E′ (90–110%).
Magnetic Bead-Based Extraction
Significantly Increased RNA Yield and
Concentration
Next, RNeasy R© Mini and Micro silica columns (both QIAGEN)
and MagMAXTM mirVanaTM (MagMAX) Total RNA Isolation
(Applied Biosystems) kits were tested for 1) RNA yield and
2) concentration with or without a post-extraction RNA
concentration step using the RNeasy R© MiniElute Cleanup Kit
(QIAGEN). In each case, PBMCs were incubated with or without
PMA/Iono for 6 h. RIN assessment demonstrated that RNA
integrity was high (>7) and consistent across all kits (Figure 2A,
left panel). RNA yield was significantly increased usingMagMAX
as compared to the RNeasy R© Mini silica column extraction
kit, for both stimulated and unstimulated PBMCs (mean yield
(µg/106 cells): 0.87 vs. 1.36, P < 0.05 and 0.82 vs. 1.42,
P < 0.01, respectively) (Figure 2A, middle panel). Moreover,
the concentration of RNA extracted from both stimulated and
unstimulated PBMCs significantly increased with the MagMAX-
RNeasy R© MiniElute combination (mean RNA concentration
(ng/µL): 23.5 vs. 83.9, P < 0.0001 and 24.8 vs. 76.6, P < 0.0001,
respectively) (Figure 2A, right panel). The RNeasy R© Micro
extraction kit had no impact on RIN, RNA yield or concentration.
Magnetic Bead-Based Extraction
Significantly Increased RT-qPCR Gene
Expression Signal Measurements
RNA extraction kit eluates were subsequently reverse transcribed
using SuperscriptTM III (ThermoFisher) and RPL13a, SDHA, TBP
as well as IFN-γ quantified by RT-qPCR. Data were normalized to
either RNA yield (copies/106 cells) or concentration (copies/µL).
When considering both yield and concentration, RT-qPCR signal
was significantly affected by extraction technique (PExt < 0.01
for all tested genes; Figure 2B). Consistent with our findings
that SDHA expression was reduced following 6 h of exposure
to PMA/Iono (Figure 1B), stimulation significantly reduced
SDHA expression (P< 0.05; Figure 2B). Similarly, consistent
with our findings that RNA yield was optimal with MagMAX
(Figure 2A), we found significantly increased gene expression
using MagMAX when compared to RNeasy R© Mini, for both
unstimulated (mean copies/106 cells: 3.4 × 108 vs. 4.9 × 108,
P < 0.0001 RPL3a; 2.1 × 107 vs. 3.6 × 107, P < 0.0001
SDHA; 5.2 × 106 vs. 8.3 × 106, P < 0.001 TBP; Figure 2B)
and stimulated (mean copies/106 cells: 6.9 × 108 vs. 9.3 ×
108, P < 0.0001 IFN-γ ; 4.0 × 108 vs. 5.2 × 108 P < 0.001
RPL13a; 5.1 × 106 vs. 7.3 × 106, P < 0.01 TBP; Figure 2B)
PBMCs. Likewise, there was a significant increase in RNA
concentration following RT-qPCR using theMagMAX-RNeasy R©
MiniElute combination when compared to RNeasy R© Mini,
for both unstimulated (mean copies/µLRT : 3.8 × 106 vs. 7.2
× 106, P < 0.0001 RPL13a; 2.3 × 105 vs. 4.2 × 105, P
< 0.001 SDHA; 5.8 × 104 vs. 1.0 × 105, P < 0.001 TBP;
Figure 2B) and stimulated (mean copies/µLRT : 7.7 × 106 vs.
1.4 × 107, P < 0.001 IFN-γ ; 4.5 × 106 vs. 7.7 × 106, P <
0.0001 RPL13a; 5.7 × 104 vs. 9.2 × 104, P < 0.0001 TBP;
Figure 2B) PBMCs. RNA yield and concentration were not
significantly affected by the RNeasy R©Micro extraction kit. When
assessing technical reproducibility, extraction method also did
not significantly affect standard deviation amongst replicate
extractions (Supplementary Table 1). These data establish that
magnetic bead-based extraction significantly enhanced RT-qPCR
signal, as compared to silica column extractions.
SuperscriptTM IV Significantly Increased
RT-qPCR Gene Expression Signal
Measurements
To identify the optimal reverse transcription kit, SuperscriptTM
III, SuperscriptTM IV (both ThermoFisher), iScriptTM Advanced
(Bio-Rad) and High-Capacity (Applied Biosystems) kits
were tested in conjunction with MagMAX (Figure 3A) and
MagMAX-RNeasy R© MiniElute (Figure 3B). A statistically
significant enhancement of RT-qPCR signal was observed with
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FIGURE 2 | RNA extraction evaluation. (A) Bioanalyser analysis of RNA Integritry Number (RIN), and nanospectrophotometer analysis of yield and concentration were
obtained using three commercially-available extraction kits with (+) or without post-extraction RNA purification and concentration. (B) RT-qPCR analysis of IFN-γ ,
RPL13a, SDHA, and TBP expression normalized to cell number (copies/106 cells) or cDNA concentration (copies/µL). 1 × 106 PBMCs paired samples were cultured
with complete media (white) or PMA/Iono (gray) for 6 h. RNA was extracted using the RNeasy® Mini (Mini) Kit, RNeasy® Micro (Micro) Kit (both QIAGEN), or
MagMAXTM mirVanaTM (MagMAX) Total RNA Isolation Kit (Applied Biosystems), with concentration step performed using the RNeasy® MiniElute Cleanup Kit
(QIAGEN). All samples were reverse transcribed with SuperscriptTM III (Invitrogen). Data were analyzed using a two-way ANOVA with post-hoc Bonferroni’s
multiple-comparisons test (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001). Biological replicate (n = 4), triplicate RNA extractions, with single reverse
transcription reactions per extraction were performed. Sample mean calculated from the mean of the technical RNA extractions which were in turn calculated from the
mean of the technical triplicate qPCR reactions. Biological mean ± biological SEM are shown.
SuperscriptTM IV as compared to SuperscriptTM III for both
unstimulated (mean copies/106 cells: 1.1× 107 vs. 1.3× 107 P <
0.05 SDHA; 4.1 × 106 vs. 5.6 × 106, P < 0.001 TBP; Figure 3A)
and stimulated (mean copies/106 cells: 5.8 × 108 vs. 6.9 × 108, P
< 0.001 IFN-γ ; 5.9 × 108 vs. 6.8 × 108, P < 0.05 RPL13a; 3.5 ×
106 vs. 4.5 × 106, P < 0.05 TBP; Figure 3A) PBMCs. Similarly,
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FIGURE 3 | Reverse transcription evaluation. Four reverse transcription kits were evalued for relative qPCR signal for (A) maximal RNA yield, or (B) maximal RNA
concentration. When maximizing RNA yield, RNA was extracted with MagMAXTM mirVanaTM (MagMAX) Total RNA Isolation Kit (Applied Biosystems); when maximizing
concentration, RNA was concentrated with RNeasy® MiniElute Cleanup Kit (QIAGEN). RNA was reverse transcribed with either SuperscriptTM III (SSIII), SuperscriptTM
IV (SSIV) (both Invitrogen), iScriptTM Advanced (iScript) (BioRad) or High-Capacity (HC) (ThermoFisher) reverse transcription kits. RNA was extracted from 1 × 106
PBMCs pared samples, cultured with complete media (white) or PMA/Iono (gray) for 6 h, then IFN-γ , RPL13a, SDHA, and TBP mRNA expression was quantified.
Data were compared with a two-way ANOVA (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 for post-hoc Bonferroni’s multiple-comparisons test). Biological replicate (n = 4),
single RNA extractions, with triplicate reverse transcription reactions per extraction were performed. Sample mean calculated from the mean of the reverse
transcription reactions calculated from the mean of the technical triplicate qPCR reactions. Biological mean ± biological SEM are shown.
SuperscriptTM IV produced the highest RT-qPCR signal following
MagMAX-RNeasy R© MiniElute extraction-concentration for
both unstimulated (mean copies/µL: 1.3 × 107 vs. 2.5 × 107,
P < 0.05 RPL13a; Figure 3B) and stimulated (mean copies/µL:
1.7 × 107 vs. 3.4 × 107, P < 0.05 IFN-γ ; 1.1 × 107 vs.
2.2 × 107, P < 0.001 RPL13a; Figure 3B) PBMCs. When
assessing technical reproducibility, extraction had no statistically
significant effect on variation between replicate extractions
(Supplementary Table 2). These data identify SuperscriptTM IV
as the superior reverse transcriptase kit irrespective of yield or
concentration strategy.
Single Cell Analytical Sensitivity Was
Observed Following Magnetic Bead-Based
RNA Extraction
We next evaluated the analytical sensitivity of our optimized
protocol using MagMAX extraction kit (Figure 4A) and
MagMAX-RNeasy R© MiniElute extraction-concentration kit
(Figure 4B). RNA was extracted from a log10 serial dilution
of unstimulated PBMCs and expression of IFN-γ , RPL13a,
SDHA, and TBP determined by absolute quantification. The
highly expressed RPL13a gene was detected at single-cell level
from both MagMAX (0.88 log10 copies/reaction; Figure 4A)
and MagMAX-RNeasy R© MiniElute combination (0.90 log10
copies/reaction; Figure 4B) extractions. Extraction technique
did not influence IFN-γ , RPL13a, or TBP expression; whilst
variability in SDHA expression (PExt < 0.05) was driven by
increased RT-qPCR signal at 105 and 104 PBMCs per extraction.
These data establish that our optimized protocol is capable of
extracting and quantifying RNA of a highly expressed gene
from a single cell. Importantly, the additional step of RNeasy R©
MiniElute Cleanup did not further enhance analytical sensitivity.
RT-qPCR Protocol Diagnostic Sensitivity
Correlates Significantly With Protein Level
Quantification of Epitope-Specific
Stimulation From as Few as 1 × 104 PBMCs
Next, we determined the diagnostic sensitivity of our optimized
RNA extraction and RT-qPCR protocol to confirm that it
accurately reflected data generated using protein-level assays.
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FIGURE 4 | Assay analytical sensitivity. Relative RT-qPCR signal for IFN-γ , RPL13a, SDHA, and TBP mRNA expression from log10 dilutions of unstimulated PBMCs
when (A) maximizing RNA yield, or (B) maximizing RNA concentration. When maximizing RNA yield, RNA was extracted with MagMAXTM mirVanaTM (MagMAX) Total
RNA Isolation Kit (Applied Biosystems); when maximizing concentration, RNA was concentrated with RNeasy® MiniElute Cleanup Kit (QIAGEN). All samples were
reverse transcribed with SuperscriptTM IV (Invitrogen). mRNA expression was determined by absolute-quantitative RT-qPCR and gene copy number per reaction was
normalized to log10 copies per reaction. Biological replicate (n = 3), single RNA extractions, with single reverse transcription reactions per extraction were performed.
Sample mean calculated from the mean of the technical triplicate qPCR reactions. Biological mean ± biological SEM are shown.
We evaluated the epitope-specific stimulatory response for four
CD8+ T cell epitopes restricted by different MHC molecules,
quantifying IFN-γ production by flow cytometry, cytokine bead
array and ELIspot; and IFN-γ mRNA by our optimized protocol.
A limited epitope-specific IFN-γ response was demonstrated by
flow cytometry (Figure 5A) and bead arrays (Figure 5B) whereas
all samples were observed to respond to stimulation by ELIspot
(Figure 5C). Importantly, our RT-qPCR protocol (Figure 6), was
able to replicate the ELIspot results but with significantly reduced
cell numbers (HLA-A1 2.5 × 104, -A2 1 × 105, -B7 1 × 104, -B8
1 × 105; 48-fold, 12-fold, and 48-fold and 12-fold, respectively;
Figure 5D).
Optimized RT-qPCR Assay Correlated With
Best-Practice Protein-Based
Immunoassays
Next, we assessed correlation between results obtained using
our optimized RT-qPCR protocol and current best-practice
immunoassays. The correlation between our RT-qPCR protocol
and ELIspot was significant at all cell numbers tested [P =
0.0006, R2 = 0.7063 (4 × 105); P = 0.0002, R2 = 0.7593 (1
× 105); P = 0.0028, R2 = 0.6065 (2.5 × 104); P = 0.0058, R2
= 0.5493 (1 × 104); Figure 5E, right panel]. The correlation
was also significant with MagPIX multiplex bead-based array
[P = 0.0056, R2 = 0.5520 (4 × 105); P = 0.0054, R2 =
0.5548 (1 × 105); P = 0.0138, R2 = 0.4707 (2.5 × 104); P =
0.0050, R2 = 0.5617 (1 × 104); Figure 5E, middle panel], but
non-significant (albeit with a similar trend) with flow cytometry
(Figure 5E, left panel). Thus, data generated using our optimized
RT-qPCR assay are consistent with best practice protein-based
immunoassays. Furthermore, our assay is capable of defining an
epitope-specific response hierarchy from as few as 1 × 104 cells,
representing a clinically and diagnostically meaningful reduction
in cell number.
Taken together, we report here a highly sensitive RNA
extraction and RT-qPCR quantification strategy using the
MagMAX RNA extraction kit, SuperscriptTM IV reverse-
transcription kit and ssoAdvancedTM SYBR master-mix
(Supplementary Table 3). This assay is sensitive to the single
cell level, can define an epitope hierarchy of response from
as few as 1 × 104 cells, and represents a sensitive and robust
alternative to protein quantification for research, diagnostic and
clinical applications.
DISCUSSION
Herein, we describe an optimized RNA extraction and RT-qPCR
protocol requiring low PBMC numbers, with high analytical
and diagnostic sensitivity, whilst maintaining high correlation
to protein-level quantification that is typically reliant on much
larger cell numbers for detection.
Precise RT-qPCR results are typically dependent on reactions
maintaining efficiency close to 100% (45). Both assay design
(e.g., primer concentration, master-mix) and sample (e.g.,
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FIGURE 5 | Assay diagnostic sensitivity. Production of IFN-γ protein was determined by flow cytometry (A), bead-based multiplex assay (MagPIX) (B), IFN-γ ELIspot
(C); or IFN-γ mRNA expression by absolute RT-qPCR (D). IFN-γ mRNA expression was correlated to measurements of protein production by flow cytometry, MagPIX
(Continued)
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FIGURE 5 | or IFN-γ ELIspot (E; left, middle and right panel, respectively). Biological replicate (n = 3) per HLA-A1, HLA-A2, HLA-B7, or HLA-B8 positive PBMCs (i.e.,
n = 12 total) were stimulated with synthetic HLA-matched peptides representing CMV, Influenza or EBV CD8+ T cell epitopes “VTE,” “GIL,” “RPH,” or “FLR” (black),
respectively. All samples were cultured with media negative control or PMA/Iono positive control. IFN-γ mRNA expression was determined by absolute quantification
RT-qPCR of titrated PBMCs (4 × 105, 1 × 105, 2.5 × 104, and 1 × 104); gene copy number per reaction was quantified by standard curve and log10 transformed.
Single RNA extractions, with single reverse transcription reactions per n, were performed. qPCR performed in technical triplicate replicates. Flow cytometry and
MagPIX performed in single wells. ELIspot performed in technical triplicate replicates. Sample mean calculated from the mean of the technical single or triplicates.
Biological mean ± technical SEM above background shown.
FIGURE 6 | Final optimized RT-qPCR assay. Steps and calculations required for the use of the optimized analytically and diagnostically sensitive RNA extraction and
RT-qPCR protocol, from peripheral blood mononuclear cells. (RNAEQ, RNA equivalent; DNAEQ, DNA equivalent).
co-extracted inhibitors) may influence PCR efficiency. We
made use of the open-access database PrimerBankTM since
those primers have been designed for use under consistent
conditions (i.e., optimal Tm 60◦C) and cover most known
human and mouse genes (55). We found primer concentration
titrations did not impact reaction efficiency, whereas the SYBR
master-mix had a significant impact. PCR inhibitors, including
hemoglobin, lactoferrin, anticoagulants, IgG, polysaccharides,
and proteases, can be co-extracted in PBMC preparations (56,
57). It is known that some DNA-polymerase variants and
PCR buffer “enhancers” have improved reaction efficiency in
the presence of such inhibitors (56, 58). The ssoAdvancedTM
master-mix, identified herein as optimal of those tested, appears
to be one such master-mix facilitating PCR efficiency in the
presence of co-extracted inhibitors. Optimization of master-
mix reagents will likely continue to be important in improving
blood-based PCR analysis and diagnostics (59, 60); especially
for accurate amplification of relatively low abundant targets,
comparisons between populations with high variability, or
amplification from inhibitor-enriched mediums (i.e., whole
blood extractions) (10, 59).
We tested three RNA extraction kits by evaluating extraction
quality and efficiency: RNeasy R© Mini Kit, RNeasy R© Micro
Kit, and MagMAXTM mirVanaTM Kit; in combination with the
RNA purification and concentration kit: RNeasy R© MiniElute
Cleanup Kit. When extracting identically controlled samples, all
kits yielded RNA with equivalent RIN scores and low technical
variability between replicates. Importantly, RNA yield from
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PBMCs was significantly increased using MagMAX as compared
to silica-column technologies. Additionally, when compared to
silica-column extractions, we found MagMAX was more cost
and time efficient when running larger number of samples (e.g.,
96 samples in ∼2 h). We therefore expect magnetic bead-based
extractions will become increasingly common within blood-
based nucleic acid isolations (59, 61, 62). In addition to extraction
techniques (e.g., silica column, phase separation), other factors
that could impact RNA quality, yield and concentration include
sample collection, storage, and transportation.
Four reverse transcriptase (RT) kits were also evaluated:
SuperScriptTM III First-Strand Synthesis System, SuperScriptTM
IV First-Strand Synthesis System, iScriptTM Advanced cDNA
Synthesis Kit and High-Capacity RNA-cDNA KitTM. Of those,
SuperscriptTM IV was associated with the highest qPCR signal.
A previous study evaluating RNA extracted from PBMCs using
earlier-generation RT kits reported >128-fold increased qPCR
signal between kits (1). We speculate that the reduced variability
that we observed between RT kits tested in our study reflects
consistent kit quality, purity of the RNA extracted by MagMAX,
or a combination thereof.
Both analytical sensitivity and diagnostic sensitivity are key
criteria for any RT-qPCR protocol. We show that the analytical
sensitivity of our assay is to the level of single cell RNA detection
for relatively highly expressed RPL13a. Sample concentration
and clean-up has been suggested to remove inhibitors and
increase sensitivity (63, 64). Unexpectedly, we found this step
did not improve our analytical sensitivity, and was time-
consuming, expensive and reduced sample volume. Nevertheless,
if concentration is warranted under specific experimental
situations, our data suggest that it is technically feasible
while retaining high analytical sensitivity. Diagnostic sensitivity
determined using MagMAX showed that an epitope response
hierarchy could be detected with as few as 1 × 104 PBMCs.
It is well-known that there is no absolute correlation between
RNA expression and protein translation. Indeed, correlations
between transcript and protein expression would be markedly
reduced under situations of epigenetic, post-transcriptional or
post-translational modification of the gene of interest (65).
Nevertheless, we correlated our optimized RT-qPCR assay with
commonly used protein-level immunoassays (flow cytometry,
cytokine bead arrays, and ELIspot) and showed a very high
correlation with the gold-standard protein-level assay, ELIspot,
as well as the commonly used MagPIX bead-based cytokine
assay, at all tested PBMC concentrations. This highlights that our
protocol represents a robust alternative to protein-based assays
(e.g., when measuring changes in cytokine mRNA expression in
PBMCs in response to specific in vitro stimulation). This work
will significantly improve analytical capacity of studies relying
on irreplaceable, relatively small or costly human samples (e.g.,
neonatal PBMCs) (66, 67).
Another important outcome of our work is the finding
that absolute quantification of transcripts and subsequent
normalization to cell numbers is the most appropriate analysis
strategy for RNA/RT-qPCR quantification from PBMCs (45, 48).
We observed significant alterations in gene expression of
commonly used reference genes RPL13a, SDHA and TBP
following stimulation. This is not unexpected as reference genes
have been described as variable across cell types, tissues, and
experimental and stimulatory conditions (25, 47, 68, 69).
In summary, we report herein the development of an
optimized PBMC RNA extraction and RT-qPCR protocol. We
employed a qPCR strategy of absolute quantification utilizing
PrimerBankTM primers and ssoAdvancedTM Universal SYBR R©
Green Master-Mix. PBMC RNA was isolated with MagMAXTM
mirVanaTM Total RNA Isolation Kit and reverse transcribed
with SuperScriptTM IV First-Strand Synthesis System. Our assay
provided single cell analytical sensitivity and a diagnostic
sensitivity that could define response hierarchy from 1 ×
104 cells. This assay offers an alternative to current best
practice protein-based immunoassays, especially for limited
PBMC numbers. This work has broad applicability for both
clinical and primary research practice.
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